These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9856125)

  • 1. [A new test for monitoring heparin therapy].
    Camici M; Evangelisti L; Giordani R
    Minerva Med; 1998 Sep; 89(9):345-9. PubMed ID: 9856125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a new protamine titration method to assay heparin in whole blood and plasma.
    Schlueter AJ; Pennell BJ; Olson JD
    Am J Clin Pathol; 1997 May; 107(5):511-20. PubMed ID: 9128262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of hexadimethrine bromide as a heparin-neutralizing agent in canine plasma.
    Green RA; LaFollette KA; Greig B
    Am J Vet Res; 1987 Mar; 48(3):496-8. PubMed ID: 3565907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of polybrene for heparin neutralization in protein C activity assay.
    Harsfalvi J; Pfliegler G; Udvardy M; Boda Z; Tornai I; Rak K
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):357-61. PubMed ID: 2133212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of heparin concentration monitoring in off-pump coronary bypass surgery.
    Baykut D; Weichelt K; Wehrle J; Zerkowski HR; Bernet F
    Eur J Med Res; 2003 Apr; 8(4):161-4. PubMed ID: 12765862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring of plasma concentration of low molecular weight heparin--comparative evaluation with chromogenic and clotting assays].
    Katagiri H; Itoh S; Uchida T; Kawai Y; Watanabe K
    Rinsho Byori; 1999 Nov; 47(11):1046-51. PubMed ID: 10590682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.
    Douglas AD; Jefferis J; Sharma R; Parker R; Handa A; Chantler J
    Angiology; 2009; 60(3):358-61. PubMed ID: 19398428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial thromboplastin time in the presence of heparin: a rapid polybrene neutralization method.
    Israels ED
    Am J Clin Pathol; 1982 Mar; 77(3):321-4. PubMed ID: 6803572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
    Eikelboom JW; Hirsh J
    Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro neutralization of heparin in plasma prior to the activated partial thromboplastin time test: an assessment of four heparin antagonists and two anion exchange resins.
    Cumming AM; Jones GR; Wensley RT; Cundall RB
    Thromb Res; 1986 Jan; 41(1):43-56. PubMed ID: 3961726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical evaluation of commonly used tests for heparin monitoring.
    Cugno M; Colombo A; Cacciabue E; Uziel L; Agostoni A
    Life Support Syst; 1986; 4 Suppl 1():120-8. PubMed ID: 3747597
    [No Abstract]   [Full Text] [Related]  

  • 19. Activated partial thromboplastin time vs heparin concentration.
    Mungall D
    Arch Intern Med; 1998 Jun; 158(11):1273-6. PubMed ID: 9625410
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring the new antithrombotic drugs.
    Walenga JM; Hoppensteadt DA
    Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.